Seegene Inc., a global leader in total solution for PCR molecular diagnostics, presented its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 in Porto, Portugal from March 16-19.
The company showcased its expertise through an exhibition booth under the theme „Elevating Confidence in HPV Screening“ and hosted symposium programs to emphasize accurate identification of high-risk HPV types related to cervical cancer is critical. Seegene’s advanced solution enhances diagnostic accuracy, enabling timely and effective detection.
Seegene presented its flagship HPV diagnostic product lineup that are designed to simultaneously detect HPV genotypes responsible for cervical cancer and/or HPV-related cancer. This capability is crucial in identifying high-risk HPV types that are known to cause cervical cancer and detecting other genotypes that are associated with benign tumors.
At the Seegene symposium on March 16, leading clinical experts from Europe discussed strategies for integrating HPV testing into real-world clinical practice. The symposium underscored the critical role of HPV testing in the early detection of cervical cancer. Additionally, the experts highlighted the advantages of self-sampling, a method that enables individuals to collect their own samples. This approach not only streamlines the testing process but also promotes the broader adoption of HPV screening.
